Jonathan Fay

Dr. Jonathan Fay

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2021 in Nature
Verified
Journal Article
Closed access
PDF file
CCCan Cao
Can Cao
HKHye Jin Kang
Hye Jin Kang
ISIsha Singh
Isha Singh
HCHe Chen
He Chen
CZChengwei Zhang
Chengwei Zhang
BRBryan L. Roth
Bryan L. Roth

30 November 2022 in Nature
Verified
Journal Article
Closed access
PDF file
SZShicheng Zhang
Shicheng Zhang
RGRyan H. Gumpper
Ryan H. Gumpper
XHXi-Ping Huang
Xi-Ping Huang
YLYongfeng Liu
Yongfeng Liu
BKBrian E. Krumm
Brian E. Krumm
BRBryan L. Roth
Bryan L. Roth

3 May 2023 in Nature
Verified
Journal Article
Open access
PDF file
JHJianming Han
Jianming Han
JZJingying Zhang
Jingying Zhang
ANAntonina L. Nazarova
Antonina L. Nazarova
SBSarah M. Bernhard
Sarah M. Bernhard
BKBrian E. Krumm
Brian E. Krumm
TCTao Che/Washington Che
Tao Che/Washington Che
The κ-opioid receptor (KOR) represents a highly desirable therapeutic target for treating not only pain but also addiction and affective disorders1. However, the development of KOR analgesics has been hindered by the associated hallucinogenic side effects2. The initiation of KOR signalling requires the Gi/o-family proteins including the conventional (Gi1, Gi2, Gi3, GoA and GoB) and nonconventional (Gz and Gg) subtypes. How hallucinogens exert their actions through KOR and how KOR determines G-protein subtype selectivity are not well understood. Here we determined the active-state structures of KOR in a complex with multiple G-protein heterotrimers—Gi1, GoA, Gz and Gg—using cryo-electron microscopy. The KOR–G-protein complexes are bound to hallucinogenic salvinorins or highly selective KOR agonists. Comparisons of these structures reveal molecular determinants critical for KOR–G-protein interactions as well as key elements governing Gi/o-family subtype selectivity and KOR ligand selectivity. Furthermore, the four G-protein subtypes display an intrinsically different binding affinity and allosteric activity on agonist binding at KOR. These results provide insights into the actions of opioids and G-protein-coupling specificity at KOR and establish a foundation to examine the therapeutic potential of pathway-selective agonists of KOR.

14 March 2023 in Biochemistry
Verified
Journal Article
Closed access
BKBrian E. Krumm
Brian E. Krumm
JDJeffrey F. DiBerto
Jeffrey F. DiBerto
ROReid H. J. Olsen
Reid H. J. Olsen
HKHye Jin Kang
Hye Jin Kang
SSSamuel T. Slocum
Samuel T. Slocum
BRBryan L. Roth
Bryan L. Roth

6 December 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
EMEdin Muratspahić
Edin Muratspahić
KDKristine Deibler
Kristine Deibler
JHJianming Han
Jianming Han
NTNataša Tomašević
Nataša Tomašević
KJKirtikumar B. Jadhav
Kirtikumar B. Jadhav
CGChristian Gruber
Christian Gruber
Despite the increasing number of GPCR structures and recent advances in peptide design, the development of efficient technologies allowing rational design of high-affinity peptide ligands for single GPCRs remains an unmet challenge. Here, we develop a computational approach for designing conjugates of lariat-shaped macrocyclized peptides and a small molecule opioid ligand. We demonstrate its feasibility by discovering chemical scaffolds for the kappa-opioid receptor (KOR) with desired pharmacological activities. The designed De Novo Cyclic Peptide (DNCP)-β-naloxamine (NalA) exhibit in vitro potent mixed KOR agonism/mu-opioid receptor (MOR) antagonism, nanomolar binding affinity, selectivity, and efficacy bias at KOR. Proof-of-concept in vivo efficacy studies demonstrate that DNCP-β-NalA(1) induces a potent KOR-mediated antinociception in male mice. The high-resolution cryo-EM structure (2.6 Å) of the DNCP-β-NalA–KOR–Gi1 complex and molecular dynamics simulations are harnessed to validate the computational design model. This reveals a network of residues in ECL2/3 and TM6/7 controlling the intrinsic efficacy of KOR. In general, our computational de novo platform overcomes extensive lead optimization encountered in ultra-large library docking and virtual small molecule screening campaigns and offers innovation for GPCR ligand discovery. This may drive the development of next-generation therapeutics for medical applications such as pain conditions.

19 March 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
RGRyan Gumpper
Ryan Gumpper
MJManish K. Jain
Manish K. Jain
KKKuglae Kim
Kuglae Kim
RSRenhong Sun
Renhong Sun
NSNing Sun
Ning Sun
BRBryan L. Roth
Bryan L. Roth
There is currently a resurgence in exploring the utility of classical psychedelics to treat depression, addiction, anxiety disorders, cluster headaches, and many other neuropsychiatric disorders. A biological target of these compounds, and a hypothesized target for their therapeutic actions, is the 5-HT2A serotonin receptor. Here, we present 7 cryo-EM structures covering all major compound classes of psychedelic and non-psychedelic agonists, including a β-arrestin-biased compound RS130-180. Identifying the molecular interactions between various psychedelics and the 5-HT2A receptor reveals both common and distinct motifs among the examined psychedelic chemotypes. These findings lead to a broader mechanistic understanding of 5-HT2A activation, which can catalyze the development of novel chemotypes with potential therapeutic utility and fewer side effects.